Oxford Biodynamics Share Discussion Threads

[applepieinthesky] 11/1/2024 06:28

Needs to keep riding before the results but maybe something is brewing behind the scenes

[hatfullofsky] 10/1/2024 16:48

Nice rise today, results due next week. Hopefully some good sales growth and an update on the prostate test plans.

[jambam] 10/1/2024 14:04

Hitman you really are a thickie aren't you

[babbler] 10/1/2024 13:52

Rns last year. People forget. Means they now have good revenue coming in

[rajraj b] 10/1/2024 13:47

Where did you hear/read this please?

[rajraj b] 10/1/2024 13:38

Looks like something is up.

[thehitman1] 10/1/2024 12:44

Watch the pumpers dump

[thehitman1] 10/1/2024 12:43

Pump and dump

[hooded claw] 09/1/2024 08:37

Do you mean Sail ?

[applepieinthesky] 08/1/2024 08:19

Looks likely to rise again today already good positive volume

[waldron] 05/1/2024 16:31

Notice of Results and Investor Webinar

21 December 2023 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch(R) 3D genomics platform expects to announce its results for the year ended 30 September 2023 on Wednesday 17 January 2024.

Following release of the results, the Company's management team will conduct a live presentation via the Yellowstone Advisory webinar platform to investors, at 3pm GMT on Wednesday 17 January 2024.


THINGS SHOULD BECOME CLEARER AS TO OUTLOOK AD RESULTS APPROACHED


CHUCKLE AND CHEERS

[waldron] 05/1/2024 16:13

GOOD LUCK TO ALL THOSE THAT SALE IN HER

[hatfullofsky] 02/1/2024 17:02

Held up well, considering the 65k sell reported late

[thehitman1] 02/1/2024 08:41

No interest at all.

[cyberbub] 27/12/2023 16:20

Sounds good but it seems like it's only for New York State? Still, better than a slap in the face with a wet fish - and perhaps other states will follow suit?

[givmesunshine] 24/12/2023 14:03

Game ChAnging piece of legislation over in the US of A - After the bell on friday , kindly posted on LSE .. Merry Christmas

Legislation S.1196-A/A.1673-A requires state-regulated insurance plans, including Medicaid, to cover biomarker testing for diagnosis, treatment, appropriate management, or ongoing monitoring of a patient’s disease or condition when the test is supported by medical and scientific evidence.

State Senator Roxanne Persaud said, "Biomarker testing has rapidly become an integral part of healthcare, as research has shown that it drastically improves outcomes for patients suffering from various illnesses and conditions, including different forms of cancer, arthritis, Parkinson's, and more. After months of dedicated effort, I'm delighted that we can give millions more New Yorkers the gift of access to this life-saving treatment just as we approach the holidays. I want to thank my cosponsor, Assembly Member Pamela Hunter, Governor Kathy Hochul, the American Cancer Society, and many other organizations who enthusiastically supported this legislation and ultimately made it possible. We would not be celebrating this achievement today without the unwavering support of those organizations and individuals who recognized that this is an issue about saving lives. Access to timely diagnosis and targeted treatment has been given a huge boost, and I am proud of our accomplishment."

Assemblymember Pamela Hunter said, "As medical capabilities progress and patients begin to see greatly improved health outcomes, we should strive to make the benefits of these new advancements as equitable as possible. With biomarker tests, patients will have access to new information that will guide treatment in a way that is more tailored to the individual. Additionally, this will help conserve medical resources as patients are given treatments that are most likely to yield results instead of going through a period of trial and error. I am proud to have sponsored this bill in New York State and I thank Governor Hochul for signing this vital legislation into law to significantly broaden the availability of these lifesaving tests."

[yellowstoneadvisory] 21/12/2023 11:06

Oxford Biodynamics will release FY results for the year to 30 September 2023 on 17 January 2024.

There will be a presentation for investors at 3pm that day and you can register for the event here.

[givmesunshine] 21/12/2023 10:20

cyber - 4.41 test per day totalling 97 (5 day week)

Presentation below - Its been updated a few times with some Cirt test cases , but no more data on the test /doctors /clinic etc.



They passed to 400 test threshold during may but overall at end of may was 335 (if you count back) and cumaltive by end of June was 432.

All quiet since..

[cyberbub] 21/12/2023 10:10

I was sure they said that they were getting 4 CIRTs per day in June. Anyway, the growth rate was exponential at that point from a low base. I do think that there will be good news in this during Q1.Nice to see the rise today

[givmesunshine] 21/12/2023 08:31

Morning

Cyber it was 97 Cirt's month in June, the 120 figure you got comes from the 100 test milestone chart which was just used to to show how quickly the 100 Test limit duration was shrinking 12 months - 4 months - 2 months to 3 tests under 1 month in June alone. Im looking for 150+ tests per month by november and will be very happy, anything over would be a bonus, as they have limited sales network.

[cyberbub] 20/12/2023 14:04

Remember there are 20,000 oncologists in the USA. All we need is for 2% of them to order 2 CIRT tests per month, and Oxford will break into profitability.